Studies have shown that aberrant activation of ERK2 in the MAPK pathway is an important cause of a variety of cancers, such as oral cancer (51) and hepatocellular carcinoma (52), in which the hyperactivation of ERK2 can be detected. This evidence concerns the gene MAPK1 and lip and oral cavity carcinoma.